Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release

Group 1 - Dyne Therapeutics has been identified as a promising investment opportunity, with Bernstein raising its price target from $12 to $21, indicating a favorable risk-reward profile [1] - The company is expected to release significant data for its treatment candidate DYN-251 for Duchenne Muscular Dystrophy (DMD), which is anticipated to be a major catalyst for the stock [1][3] - Dyne Therapeutics reported in its Q3 2025 earnings that both of its lead programs, DYNE-251 for DMD and DYNE-101 for Myotonic Dystrophy Type 1, received Breakthrough Therapy Designation from the FDA, highlighting the potential of its FORCE platform [2] Group 2 - Dyne Therapeutics plans to launch two potentially best-in-class medicines within approximately one year, starting with DYNE-251 for DMD, with topline data from a primary analysis expected in December 2025 [3] - The company aims to support a potential submission for US Accelerated Approval in Q2 2026 based on the upcoming data [3]